Application of carbon monoxide-releasing molecules and heparin in preparing medicament for treating sepsis

A technology for carbon monoxide and sepsis, applied in the direction of drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve problems such as blood coagulation damage, achieve reduced dosage, easy and correct concentration control, and meet clinical applications Effect

Inactive Publication Date: 2010-02-10
AFFILIATED HOSPITAL OF JIANGSU UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, single use of large doses of heparin in sepsis can cause greater damage to coagulation function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of carbon monoxide-releasing molecules and heparin in preparing medicament for treating sepsis
  • Application of carbon monoxide-releasing molecules and heparin in preparing medicament for treating sepsis
  • Application of carbon monoxide-releasing molecules and heparin in preparing medicament for treating sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Preparation of the drug:

[0022] Mix 20.5 mg of carbon monoxide releasing molecules with 1 ml of DMSO to obtain a preparation A with a concentration of 40 mM, and use it at a dose of 8 mg / kg body weight; mix and dilute 20,000 IU / 2 ml of heparin with normal saline 10 times to obtain 1,000 IU / L Heparin solution preparation B is used at a dose of 100 IU / kg body weight.

Embodiment 2

[0024] Effects of CORM-2+ultramicrodose heparin on WBC, PLT count, plasminogen (PLG) and antithrombin III (AT-III) activity in septic mice.

[0025] experiment method:

[0026] (1) Animal and CLP sepsis model

[0027] Male C57BL / 6 mice, 6-8 weeks old, weighing 18±2 grams, were raised in a general laboratory (commercial dry block feed, free access to water). The experimental animals were divided into three groups according to the random number table method: Sham group (n=9), CLP group (n=9) and CLP+CORM-2+heparin group (n=9).

[0028] Under isoflurane inhalation anesthesia, the mice in the CLP group were subjected to cecal ligation and perforation, and 1.5ml of normal saline was injected intraperitoneally after injury to resist shock; the mice in the CLP+CORM-2+heparin group were injected with CORM-2 (8mg / kg), and at the same time intraperitoneally inject heparin 100U / kg body weight.

[0029]Wherein: the medicine used in the Sham group is normal saline, the medicine used in...

Embodiment 3

[0050] Effects of CORM-2+ultramicrodose heparin on coagulation system and platelet aggregation in septic mice

[0051] experiment method:

[0052] (1) Animal and CLP sepsis model

[0053] Male C57BL / 6 mice, 6-8 weeks old, weighing 18±2 grams, were raised in a general laboratory (commercial dry block feed, free access to water). The experimental animals were divided into three groups according to the random number table method: Sham group (n=9), CLP group (n=9) and CLP+CORM-2+heparin group (n=9). Under isoflurane inhalation anesthesia, the mice in the CLP group were subjected to cecal ligation and perforation, and 1.5ml of normal saline was injected intraperitoneally after injury to resist shock; the mice in the CLP+CORM-2+heparin group were injected with CORM-2 (8mg / kg), and at the same time intraperitoneally inject heparin 100U / kg body weight. All animals were sacrificed with isoflurane inhalation 24 hours after injury and collected specimens.

[0054] (2) Detection indi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of carbon monoxide-releasing molecules and heparin in preparing a medicament for treating sepsis. The carbon monoxide-releasing molecules are combined with the ultramicro heparin to improve the coagulation defects of the sepsis, the control of the concentration of the carbon monoxide-releasing molecules and the heparin is relatively easy and correct, the carbon monoxide-releasing molecules and the heparin can be conveniently added when used for a long time, simultaneously the consumption and side effect of the heparin are reduced, and the carbon monoxide-releasing molecules and the heparin can meet the requirement of clinical application. The carbon monoxide-releasing molecules are combined with the ultramicro heparin to improve the coagulation defects ofthe sepsis, the control of the concentration of the carbon monoxide-releasing molecules and the heparin is relatively easy and correct, the carbon monoxide-releasing molecules and the heparin can beconveniently added when used for a long time, and the carbon monoxide-releasing molecules and the heparin can meet the requirement of clinical application.

Description

technical field [0001] The present invention relates to the new application of carbon monoxide releasing molecule and heparin, specifically, relates to a carbon monoxide releasing molecule combined with ultra-micro dose heparin, which can be used early to treat blood coagulation dysfunction in sepsis. Background technique [0002] Sepsis is a common complication after severe trauma, shock and infection. Further development can lead to septic shock and multiple organ dysfunction syndrome (MODS). Clinical treatment still has little effect, and the mortality rate remains high. Studies have shown that vital organ failure after severe sepsis, especially multiple organ failure, has a high mortality rate. Once multiple organ failure occurs, existing treatment measures are difficult to reverse it, so it is particularly important to prevent or reduce early organ damage in sepsis. The coagulation function changes in the early stage after sepsis, and the degree of systemic inflammato...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/727A61P7/04A61P31/00A61P43/00
Inventor 孙炳伟刘东明陈曦
Owner AFFILIATED HOSPITAL OF JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap